AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%
Last update at 2024-04-25T20:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 234.35M | 294.15M | 130.84M | 398.11M | 452.09M |
| Minority interest | - | - | - | - | - |
| Net income | 182.28M | 231.06M | 111.78M | 321.01M | 690.07M |
| Selling general administrative | 459.86M | 401.71M | 293.36M | 228.24M | 206.37M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 1553.15M | 1382.10M | 951.27M | 934.68M | 827.48M |
| Reconciled depreciation | 20.88M | 13.63M | 9.14M | 8.35M | 7.77M |
| Ebit | 180.61M | 273.04M | 100.92M | 361.12M | 444.32M |
| Ebitda | 201.48M | 286.67M | 110.06M | 369.47M | 452.09M |
| Depreciation and amortization | 20.88M | 13.63M | 9.14M | 8.35M | 7.77M |
| Non operating income net other | -0.19700M | -0.18400M | 0.91M | 0.68M | 0.40M |
| Operating income | 201.48M | 286.67M | 110.06M | 369.47M | 438.86M |
| Other operating expenses | 1409.58M | 1148.30M | 877.48M | 598.30M | 414.97M |
| Interest expense | 53.74M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Tax provision | 52.07M | 63.09M | 19.06M | 77.10M | -237.97800M |
| Interest income | 33.06M | 7.67M | 19.86M | 27.96M | 12.84M |
| Net interest income | 33.06M | 7.67M | 19.86M | 27.96M | 12.84M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 52.07M | 63.09M | 19.06M | 77.10M | -237.97800M |
| Total revenue | 1611.06M | 1434.97M | 987.54M | 967.77M | 853.83M |
| Total operating expenses | 1351.67M | 1095.43M | 841.21M | 565.21M | 388.62M |
| Cost of revenue | 57.91M | 52.87M | 36.27M | 33.10M | 26.35M |
| Total other income expense net | 32.87M | 7.49M | 20.78M | 28.64M | 13.24M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 182.28M | 231.06M | 111.78M | 321.01M | 690.07M |
| Net income applicable to common shares | 182.28M | 231.06M | 111.78M | 321.01M | 690.07M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 3071.49M | 2616.24M | 2137.33M | 1885.67M | 1422.29M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 62.21M | 57.53M | 57.01M | 26.99M | 15.02M |
| Total liab | 583.06M | 405.62M | 258.22M | 199.70M | 134.83M |
| Total stockholder equity | 2488.43M | 2210.61M | 1879.11M | 1685.97M | 1287.45M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 285.11M | 313.33M | 181.03M | 21.72M | 21.82M |
| Common stock | 0.32M | 0.32M | 0.31M | 0.30M | 0.30M |
| Capital stock | 0.32M | 0.32M | 0.31M | 0.30M | 0.30M |
| Retained earnings | -34.22500M | -216.50700M | -447.57000M | -559.35100M | -880.36300M |
| Other liab | 68.53M | 16.76M | 4.48M | 8.94M | 17.18M |
| Good will | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M |
| Other assets | 286.88M | 197.54M | 187.11M | 185.32M | 247.63M |
| Cash | 501.19M | 647.17M | 319.22M | 266.50M | 314.77M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 324.36M | 337.59M | 204.66M | 142.75M | 105.47M |
| Current deferred revenue | 6.58M | 8.74M | - | 106.72M | 15.90M |
| Net debt | -311.02500M | -595.89700M | -270.13100M | -215.76200M | -302.59700M |
| Short term debt | - | -8.73900M | - | 2.73M | 56.85M |
| Short long term debt | - | - | - | - | 2.74M |
| Short long term debt total | 190.17M | 51.27M | 49.09M | 50.74M | 12.18M |
| Other stockholder equity | 2536.85M | 2427.56M | 2321.89M | 2241.95M | 2168.22M |
| Property plant equipment | 110.62M | 149.15M | 67.38M | 48.89M | 56.76M |
| Total current assets | 1618.76M | 1834.75M | 1445.39M | 1011.19M | 897.02M |
| Long term investments | 756.73M | 371.11M | 332.31M | 536.38M | 157.19M |
| Net tangible assets | 2424.74M | 2048.76M | 1815.43M | 1622.29M | 1223.77M |
| Short term investments | 807.27M | 819.90M | 887.32M | 585.74M | 378.56M |
| Net receivables | 214.78M | 282.65M | 160.88M | 119.07M | 178.83M |
| Long term debt | - | - | - | - | 12.10M |
| Inventory | 33.30M | 27.49M | 20.97M | 12.89M | 9.84M |
| Accounts payable | 32.67M | 24.26M | 23.63M | 11.58M | 10.90M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -14.52100M | -0.75800M | 4.48M | 3.07M | -0.70100M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 0.32M | - | 0.31M | 0.30M | 0.30M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | -34.22500M | - | -447.57000M | -559.35100M | -880.36300M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 290.58M | 131.00M | 71.85M | 11.31M | 3.52M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1452.73M | 781.49M | 691.94M | 874.48M | 525.27M |
| Capital lease obligations | 190.17M | 51.27M | 49.09M | 50.74M | 12.18M |
| Long term debt total | - | - | - | - | 0.08M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -385.95800M | 21.34M | -100.87000M | -574.41300M | -264.86100M |
| Change to liabilities | -37.22300M | 66.10M | 51.11M | 44.12M | 14.15M |
| Total cashflows from investing activities | -524.41400M | -42.88400M | -131.21500M | -587.24700M | -297.85000M |
| Net borrowings | - | - | - | - | -0.01300M |
| Total cash from financing activities | 0.59M | -14.80100M | -25.13200M | 12.55M | 9.69M |
| Change to operating activities | -91.32400M | 30.42M | -25.83100M | -5.72300M | -8.52500M |
| Net income | 182.28M | 231.06M | 111.78M | 321.01M | 690.07M |
| Change in cash | -161.21400M | 343.12M | 52.63M | -47.73800M | 127.56M |
| Begin period cash flow | 663.89M | 320.77M | 268.14M | 315.88M | 188.31M |
| End period cash flow | 502.68M | 663.89M | 320.77M | 268.14M | 315.88M |
| Total cash from operating activities | 362.61M | 400.80M | 208.98M | 526.96M | 415.72M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 20.88M | 13.63M | 9.14M | 8.35M | 7.77M |
| Other cashflows from investing activities | -110.75000M | -10.00000M | -10.00000M | -574.41300M | 0.31M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -11.68300M | -13.20900M | -21.89700M | -5.73100M | -3.18100M |
| Change to account receivables | 66.85M | -122.32400M | -42.47000M | 43.72M | -85.47100M |
| Sale purchase of stock | 23.89M | 24.31M | 24.89M | 22.50M | -314.77500M |
| Other cashflows from financing activities | -47.18600M | -39.10800M | -25.13200M | -9.94600M | 9.70M |
| Change to netincome | 153.94M | 195.12M | 123.37M | 127.69M | -206.05200M |
| Capital expenditures | 138.46M | 64.22M | 30.34M | 12.83M | 33.30M |
| Change receivables | 66.85M | - | -42.47000M | 43.72M | -89.88100M |
| Cash flows other operating | -12.42700M | - | -22.05200M | -12.20500M | 5.70M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -161.21400M | - | 52.63M | -47.73800M | 127.56M |
| Change in working capital | -12.79900M | -39.01300M | -40.14000M | 67.08M | -79.76300M |
| Stock based compensation | 107.57M | 119.82M | 105.07M | 56.60M | 44.32M |
| Other non cash items | 125.04M | 28.77M | 7.87M | 2.91M | -2.56700M |
| Free cash flow | 224.16M | 336.58M | 178.64M | 514.12M | 382.42M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| EXEL Exelixis Inc |
-0.18 0.76% | 23.53 | 82.21 | 22.73 | 4.09 | 3.10 | 3.58 | 95.92 |
| NVO Novo Nordisk A/S |
-0.37 0.29% | 125.79 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-3.3 2.60% | 123.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-3.06 0.76% | 397.70 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
0.06 0.07% | 90.16 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
1851 Harbor Bay Parkway, Alameda, CA, United States, 94502
| Name | Title | Year Born |
|---|---|---|
| Dr. Stelios Papadopoulos Ph.D. | Co-Founder & Independent Chair of the Board | 1948 |
| Dr. Michael M. Morrissey Ph.D. | CEO, Pres & Director | 1961 |
| Mr. Christopher J. Senner | Exec. VP & CFO | 1968 |
| Dr. Peter Lamb Ph.D. | Exec. VP of Scientific Strategy & Chief Scientific Officer | 1961 |
| Mr. Jeffrey J. Hessekiel J.D. | Exec. VP, Gen. Counsel & Sec. | 1969 |
| Mr. Patrick J. Haley M.B.A., MBA | Exec. VP of Commercial | 1976 |
| Dr. Dana T. Aftab Ph.D. | Exec. VP of Bus. Operations | NA |
| Ms. Susan T. Hubbard | Exec. VP of Public Affairs & Investor Relations | NA |
| Mr. Gregg Bernier | VP of Marketing | NA |
| Ms. Laura Dillard | Exec. VP of HR | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...